MedTech Innovator

Discure Technologies is focused on creating a minimally invasive, implantable bioelectronic device aimed at treating degenerative disc disease (DDD). This innovative device employs a novel bioelectric technique that addresses the root cause of DDD, allowing physicians to alleviate pain and restore normal disc function in patients. By promoting healing of the affected discs, Discure seeks to improve the quality of life for individuals suffering from this condition.

Leadoptik is a California-based company operating in stealth mode, focused on developing advanced miniature imaging technology for minimally invasive medical procedures. This innovative technology enhances surgeons' ability to view small objects with improved clarity compared to existing imaging systems, offering 3D navigation capabilities and high-resolution imaging. By facilitating the early detection of cancer in patients, Leadoptik aims to significantly improve surgical outcomes and patient care.

EvoEndo is a medical technology company focused on advancing unsedated endoscopic procedures for both pediatric and adult patients. The company has developed a system that incorporates sterile, single-use flexible endoscopes, a virtual reality-based distraction method, and a comprehensive software integration platform. This innovative approach allows for routine endoscopies to be performed in a clinical setting without the need for general anesthesia or sedation. By streamlining the process, EvoEndo's technology aims to decrease complexity, lower costs, and alleviate the anxiety often associated with endoscopic procedures, making them more accessible and manageable for patients and healthcare providers alike.

TrackX Technology develops a tracking technology that provides real-time virtual live fluoroscopy. It focuses on creating profound procedurally driven imaging solutions that provide priceless benefits to the surgeon, hospital, and entire operating room.

Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.

New View Surgical, Inc. is a Boston-based medical device company that specializes in the development and commercialization of the VisionPort technology, a novel surgical imaging and access system designed for minimally invasive surgery. Founded in 2009, the company has created a proprietary system that integrates four essential devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. This innovation aims to provide surgeons with enhanced control over visualization and instrumentation during procedures, addressing various unmet needs within the surgical market. The leadership team comprises experienced professionals in medical device innovation and commercialization, dedicated to delivering impactful solutions that offer both clinical and economic benefits to operating rooms worldwide.

OncoRes Medical Pty Ltd is an early-stage medical device company based in Nedlands, Australia, founded in 2014. The company specializes in developing a patented imaging technology that provides surgeons with real-time, micro-scale images of tissue stiffness and elasticity during breast cancer surgeries. This innovative tool integrates optical coherence tomography to enhance surgical accuracy, aiding in the differentiation between tumor and healthy tissue. OncoRes collaborates with leading researchers at the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons in the Western Australian public health system. With support from the Medical Research Commercialisation Fund, OncoRes Medical aims to improve clinical applications by enabling precise intraoperative assessments of tissue microstructure, ultimately striving to transform the standard of care in breast cancer treatment.

Evergaze, Inc. is a company based in Richardson, Texas, that focuses on developing innovative visual aids for individuals with macular degeneration. Established in 2016, Evergaze has created a unique device that consists of prescription glasses equipped with a monocular electronic vision augmentation system on one lens. The founding team comprises experienced engineers who have leveraged their expertise from various technical sectors to design this product. The seeBoost® device was developed through extensive collaboration with patients, practitioners, and researchers in the field of low vision, embodying a commitment to addressing the needs of those affected by visual impairments.

Pristine Surgical LLC, founded in 2011 and based in Manchester, New Hampshire, has developed a groundbreaking single-use digital imaging platform tailored for surgical and diagnostic rigid endoscopic procedures. The company specializes in single-use digital arthroscopes and laparoscopes that come in a completely sterile kit. By integrating high-definition digital imaging, advanced LED lighting, artificial intelligence, and cloud-based software, Pristine Surgical aims to enhance the efficiency and safety of over 23 million procedures annually. The platform not only improves the surgical experience for patients and healthcare providers but also addresses key concerns such as cost reduction, risk mitigation, and the elimination of cross-contamination associated with reprocessing instruments. Through its innovative technology, Pristine Surgical strives to streamline the entire surgical episode, ultimately improving communication and satisfaction among surgeons and healthcare facilities.

Avisi Technologies Inc. is focused on developing innovative solutions to combat glaucoma, a leading cause of irreversible blindness. The company has created VisiPlate, a next-generation aqueous shunt designed for mid to late-stage glaucoma treatment. This product is notable for its ultrathin design, being 20 times thinner than a human hair, which facilitates a less invasive insertion procedure that reduces operating time and simplifies follow-up care. VisiPlate is constructed from alumina, a material recognized for its use in hip replacements, thus ensuring biocompatibility. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Avisi Technologies aims to address the challenges associated with current glaucoma treatments, including patient non-compliance and post-operative complications, ultimately striving to prevent blindness in affected individuals.

Darmiyan, Inc. is a company that specializes in the development of diagnostic software aimed at the early detection and monitoring of Alzheimer's disease and other neurodegenerative disorders. Based in San Francisco and founded in 2014, the company offers BrainSee, a Software as a Service platform that utilizes non-invasive brain MRI scans to produce detailed brain maps. This innovative tool quantifies neurodegeneration in individual brain voxels and generates a summary score reflecting brain health and the risk of cognitive decline. BrainSee operates using proprietary technology, referred to as The Virtual Microscope, which provides insights into brain cell distortion before clinical symptoms manifest. The algorithm has undergone successful third-party validation in the US and Canada, demonstrating its accuracy in predicting mild cognitive impairment. By leveraging advanced medical imaging and artificial intelligence, Darmiyan aims to enhance early diagnosis and intervention for patients with neurodegenerative diseases.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, focused on enhancing the treatment options for patients with brain tumors. Founded in 2017, the company has developed GammaTile, an innovative medical device that integrates a biocompatible collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a conformable and bioresorbable solution that can potentially prevent disease progression and improve patient quality of life. GammaTile has received multiple patents and has shown promise in clinical trials, with significant improvements observed in patients treated at the Barrow Neurological Institute. This approach aims to revolutionize care for the estimated 176,000 individuals diagnosed with brain tumors annually in the United States.

ITGI Medical is a bio-medical engineering company specializing in research and development, design, manufacture and distribution of high quality heterologous tissue covered stents for Cardiovascular and Neurovascular interventions. Their focus is on current technologies and applications that improve the standard of care for patients around the world in the fields of interventional Cardiology and Interventional Neuro-Radiology for the application in Coronary and neurological aneurysms, treatment of Fistulas, Saphenous Vein Graft occlusion (SVG Disease) and vascular perforations. Studies conducted prove that ITGI’s propriety technology can address these clinical problems in a safe and effective manner.

Centerline Biomedical, Inc. is a Cleveland-based company founded in 2014, focused on developing advanced navigation systems for interventional vascular procedures. The company specializes in a non-x-ray based, three-dimensional GPS surgical navigation technology that enhances the precision and outcomes of endovascular procedures while significantly reducing radiation exposure for both patients and healthcare providers. This innovative system assists surgeons in accurately navigating catheters and guide wires through the complex three-dimensional anatomy of patients with vascular diseases, ultimately enabling safer and more effective image-guided surgeries. The technology is rooted in research and development from the Cleveland Clinic, highlighting its commitment to improving surgical practices in the medical field.

EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.

Augmedics is a provider of augmented reality (AR) surgical image guidance solutions. Augmedics seeks to improve healthcare by developing cutting-edge technologies that will revolutionize surgical treatment. The company’s first product, the xvision-spine (XVS) system, is an augmented-reality surgical navigation system designed to allow surgeons to see and navigate inside a patient’s body during complex procedures.

Emmetrope is developing next-generation accommodative lenses. The holy grail of accommodative lenses must deliver a lens that accommodates at least two diopters, has a stable effect, is placed in the capsular bag and is compatible with modern cataract technique. Emmetrope is well on its way to achieving this goal. They are a small angel-funded company, but they have taken their first lens, called Actalens™, through clinical testing. The results, presented at ESCRS and currently in press, show that their lens outperforms other lenses in terms of anterior movement with accommodation. This accommodative movement has recently been independently validated and shown to be stable out to 20 months post surgery. Emmetrope, despite its size, now has best in class movement and stability of effect. Their final push toward the ultimate accommodative lens is about to begin. Computer modeling with finite element analysis demonstrates that their ActaLens platform, in its two layer embodiment, will yield a shape-change lens that offers over three diopters of accommodation. They are seeking series A financing to model, produce and clinically test this next generation shape change lens as well as take their first generation lens through CE mark and launch. The two year goal is specific and would have tremendous financial return for their company. They want to employ their validated Actalens platform to produce a shape-change lens with unprecedented objective accommodation.

Adult Medical Predictive Devices, Diagnostics and Displays, Inc. (AMP3D) has developed a platform for analytics and displays that makes sense of “Big Data” in health care. AMP3D at a glance enables earlier intervention and better outcomes by predicting potentially catastrophic events like emergent intubation, hemorrhage, and severe sepsis that can quadruple mortality and increase lengths-of-stay by more 9 days on average. AMP3D will use demonstrable return-on-investment to sell its platform as a service on a value-based pricing basis, aimed directly at quality measures and performance standards that impact reimbursement and payment. A 20% reduction in emergent intubations at a single medical ICU, for example, can save $600,000 annually; the addressable overall market opportunity for the in-patient market alone is in the billions of dollars.

Bionic Vision Technologies Pty Ltd is an Australian company focused on developing visual prostheses aimed at restoring vision to individuals affected by blindness, particularly those with inherited retinal diseases. Founded in 2007 and based in Carlton, the company creates a suprachoroidal visual implant system that works by electrically stimulating the remaining retinal cells in patients with retinal degeneration. The innovative devices operate by capturing images through a camera mounted on an eyeglass frame, which are then converted into electrical signals. These signals stimulate the nerves using electrodes placed behind the retina, allowing visual information to be transmitted to the brain. Through this technology, Bionic Vision Technologies seeks to improve the quality of life for blind patients by enhancing their eyesight.

Diagnostic Photonics, Inc. specializes in advanced imaging technologies designed to aid physicians in the real-time assessment of tissue microstructure. Founded in 2008 and headquartered in Chicago, Illinois, the company has developed the Foresee Imaging System, which produces diffraction-corrected images to enhance tissue evaluation. The innovative imaging technology stems from research conducted at the Beckman Institute for Advanced Science and Technology at the University of Illinois, known for its interdisciplinary approach to scientific advancement.

2C Tech Corporation, based in Irvine, California, is a biotech company specializing in the development of medical devices that utilize nanotechnology for ophthalmic applications. The company's flagship product, SeeQ, employs intraocularly delivered photoactive nanoparticles to convert light into electrical energy, functioning similarly to a solar cell. 2C Tech is dedicated to creating innovative therapies for retinal degenerative conditions, particularly focusing on Retinitis Pigmentosa, a disease for which there are currently no effective treatments. The company's research also aims to address other serious eye conditions, including certain forms of Macular Degeneration, Glaucoma, and Diabetic Retinopathy, which affect larger patient populations. By leveraging its expertise in nanoparticle technologies, 2C Tech seeks to provide meaningful therapeutic benefits for those suffering from these debilitating diseases.

LensGen, Inc. is an ophthalmic medical device company based in Irvine, California, that focuses on developing innovative solutions for presbyopia and cataracts. Founded in 2011, the company has created a biomimetic, curvature-changing intraocular lens designed to mimic the natural human lens. This lens, known as Juvene™, utilizes the eye's natural muscle contractions to adjust its shape and dioptric power on demand, allowing for clear and continuous vision at all distances. By restoring youthful vision, LensGen's technology eliminates the need for reading glasses, offering a significant advancement in the treatment of age-related vision issues.

LensGen, Inc. is an ophthalmic medical device company based in Irvine, California, that focuses on developing innovative solutions for presbyopia and cataracts. Founded in 2011, the company has created a biomimetic, curvature-changing intraocular lens designed to mimic the natural human lens. This lens, known as Juvene™, utilizes the eye's natural muscle contractions to adjust its shape and dioptric power on demand, allowing for clear and continuous vision at all distances. By restoring youthful vision, LensGen's technology eliminates the need for reading glasses, offering a significant advancement in the treatment of age-related vision issues.

Vital Enterprises develops augmented reality software designed to enhance the performance of technicians engaged in complex manual tasks, particularly in manufacturing and field servicing environments. The company's innovative software, compatible with smart glasses, offers hands-free communication and an intuitive data display that supports skilled operators during assembly and maintenance activities. With features such as a comprehensive Augmented Reality Dashboard, technicians can access work instructions without the need for physical interaction, allowing them to check off and log each task step efficiently. Additionally, the software includes a see-what-I-see telepresence capability, which enables remote experts to provide immediate assistance, thereby improving operational efficiency and safety in sectors like healthcare.

Viderics is developing a continuous transthoracic echocardiography (cTTE) system to acquire continuous, repeatable ultrasonic views of the heart without an attending sonographer. It will include software to calculate ejection fraction, stroke volume and cardiac output by analyzing the continuous stream of heart images. The system’s initial intended clinical application will be hemodynamic monitoring of patients at high cardiac risk in critical care, surgery, pre-op, and step-down care. The primary indication will be for patients unresponsive to standard care protocols and whose cardiac condition may change rapidly.

Mighty Oak Medical specializes in developing advanced medical equipment focused on improving surgical outcomes in spinal procedures. Founded in 2011 and headquartered in Colorado, the company has created the innovative FIREFLY Technology, which utilizes a patient's 3D imaging data to produce custom surgical guides through 3D printing. This technology provides an affordable and disposable option for surgical navigation, allowing surgeons to achieve an optimal screw trajectory with greater precision. By offering patient-specific guides and pre-surgical plans, Mighty Oak Medical aims to enhance the accuracy and cost-effectiveness of spinal surgeries, ultimately prioritizing patient-centered care.

Yolia Health, based in Mexico City, specializes in developing medical equipment aimed at preserving, restoring, and enhancing vision. The company's flagship product, the True Vision Treatment (TVT), is a non-invasive approach to correcting vision issues such as presbyopia. This innovative treatment allows patients to self-administer a combination of customized contact lenses and specially formulated eye drops in the comfort of their own homes. Remarkably, after just five days of treatment, patients can cease using both the TVT Contacts and Eye Drops, as well as their reading glasses, for up to 12 months before requiring re-treatment. Yolia Health's approach uniquely improves both near and distance vision without compromising either, setting it apart from other alternatives in the market. The company is currently seeking sophisticated investors and key industry partners to further its mission.

LIM Innovations, founded in 2012 by a prosthetist and an orthopedic surgeon, addresses the challenges of traditional prosthetic sockets through innovative design and technology. The company specializes in fully adjustable socket prosthetics tailored for amputees, utilizing 3D digital imaging to create custom-molded devices that fit individual limbs. These modular and adjustable prosthetics are crafted from advanced materials and textiles, enhancing comfort and mobility for users. By integrating insights from the action sports industry, LIM Innovations strives to improve functional outcomes and streamline the prosthetic provisioning process, ultimately enhancing the quality of life for amputees.